Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Join us for this interactive live Webinar featuring global expert perspectives on the latest data from ELCC on antibody drug conjugates in NSCLC, including discussion around patient cases and the opportunity to get your questions answered by the experts.

Sign up now!

Thank you for your interest in attending the Clinical Care Options (CCO) live Webinar, “Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC.”

This live Webinar will feature expert faculty, and provide interactivity, evidence-based content, and panel discussions. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you, CCO Member Services


Welcome, Introduction, Polling Questions

Introduction: Novel ADCs for Treatment of NSCLC – Professor Smit

Activity of ADCs in Clinical Trials for Lung Cancer

  • HER2-altered NSCLC, HER3-positive NSCLC – Dr. Yu
  • TROP-2–positive NSCLC, CEACAM5, c-Met–positive NSCLC – Dr. Planchard

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC

Summary, Final Thoughts, Audience Q&A


Date / Time
Event Details


Program Director
Egbert F. Smit, MD, PhD

Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

David Planchard, MD, PhD

Associate Professor of Medicine
Department of Medicine at Gustave Roussy
Villejuif, France

Helena Yu, MD

Assistant Attending 
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate new and emerging prognostic and predictive biomarkers into NSCLC treatment paradigms.

Target Audience
This program is intended for global medical oncologists, pathologists and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the clinical rationale for assessing HER2, HER3, and TROP2 in the metastatic setting for NSCLC
  • Appraise the available clinical data on HER2-, HER3-, and TROP2-targeted antibody–drug conjugates in NSCLC
  • Plan therapeutic strategies for appropriate patients with HER2-altered NSCLC
  • Identify patients eligible to enroll on important ongoing clinical trials based evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.